In this study, we show that therapeutic stress induces a previously unrecognized STAT1 modification that weakens tumor immune response, linking prior targeted therapy to immunotherapy resistance and highlighting implications for treatment scheduling and patient stratification. This evidence concerns the gene STAT1 and neoplasm.